Diabetic Kidney Disease at a Tipping Point: Kidney Week Offerings

  • 1 Katherine R. Tuttle, MD, is a member of the ASN Diabetes Kidney Disease Collaborative and is affiliated withProvidence Health Care, the Kidney Research Institute, the Institute of Translational Health Sciences, and the University of Washington School of Medicine. Meaghan Allain is a senior project associate at ASN.
Full access

For nearly 20 years, the field of diabetic kidney disease (DKD) was essentially stalled without impactful therapeutic advances. However, that landscape has dramatically changed with the recent discovery of kidney and cardiovascular benefits from SGLT2 inhibitors and GLP-1 receptor agonists. In response to these recent advancements, the American Society of Nephrology (ASN) has launched the Diabetic Kidney Disease Collaborative (DKD-C), which is working to raise awareness and to promote dissemination and implementation of optimal treatment to patients with, and at risk for, DKD.

Because a central goal of the DKD-C is to provide education and tools to help nephrologists and other healthcare professionals provide high-quality care for DKD, this year’s Kidney Week is filled with a number of robust sessions squarely focused on diabetes, metabolism, and the kidney.

The DKD-specific educational opportunities available during this year’s Kidney Week include a two-day early program, as well as basic, clinical, and translational science sessions with state-of-the-art lectures. These sessions cover evidence from the recent blockbuster clinical trials of new therapies and also emphasize implementation of current standards of care and lifestyle approaches to manage DKD. What an exciting time, truly a tipping point, in the field of DKD!

A complete listing of Kidney Week opportunities for diabetic kidney disease can be found here: Be sure to attend the late-breaking clinical trials sessions for cutting-edge data on DKD (and other therapeutic areas).


In addition to the breakthrough therapies announced in 2019, there are numerous clinical trials in the pipeline that are sure to have an impact on the way DKD is managed, further expanding the menu of treatment options available. Stay tuned.